SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (8)7/30/1996 9:40:00 PM
From: Josh C. Pleasure, M.D.   of 371
 
You can expect announcement of phase III trials of CEA-Scan for breast cancer diagnosis. THere have been many reports from literature and meetings about ability of CEA-Scan in conjunction with mammography to avoid unnecessary breast biopsies. 1st doses of CEA-Scan for this purpose will be available soon.

I trust you saw initiation of phase III trials for LymphoScan? LL2, the antibody portion of LymphoScan will also be conjugated with a therapeutic radioisotope and used for treatment of non-Hodgkin's lymphoma. Hopefully, they won't have the same myelosuppression side effect problems that others have had up to this point. They may even try to use their avidin/biotin conjugates to increase dose without increasing side effects (that's speculation on my part).

Don't forget submission of LeukoScan for FDA approval and final marketing approval in Europe for LeukoScan and CEA-Scan - both could happen by September 1996.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News